Social Links

Follow on Facebook Follow on TwitterFollow EiR on PinterestFollow EiR on Instagram

Xpert Access

×

Login To Get Involved!


Forgot your username?


Forgot your password?

×

Join Us At EiR Now!

DNRS Roof Banner

 

DNRS Interactive DVD Series & Seminars

Celiac Disease: From Pathogenesis to Novel Therapies

 

 

 

 

Gastroenterology. 2009 Sep 17. [Epub ahead of print]

 

Celiac Disease: From Pathogenesis to Novel Therapies.

 

Schuppan D, Junker Y, Barisani D. Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

 

 

Celiac disease (cd) has become one of the best understood human lymphocyte antigen-linked disorders. While it shares many immunological features with inflammatory bowel disease, cd is uniquely characterized by 1) a defined trigger (gluten proteins from wheat and related cereals), 2) the necessary presence of HLA-DQ2 or -DQ8, and 3) the generation of circulating autoantibodies to the enzyme tissue transglutaminase (TG2). TG2 deamidates certain gluten peptides increasing their affinity to HLA-DQ2 or -DQ8. This generates a more vigorous CD4+ T helper 1 T cell activation which can result in intestinal mucosal inflammation, malabsorption, and numerous secondary symptoms and autoimmune diseases. Moreover, gluten elicits innate immune responses that act in concert with the above adaptive immunity. Exclusion of gluten from the diet reverses many disease manifestations, but is usually not or less efficient in patients with refractory cd or associated autoimmune diseases. Based on the advanced understanding of cd pathogenesis, targeted nondietary therapies have been devised, and some of these are already in phase 1 or 2 clinical trials. Examples are 1) modified flours that have been depleted of immunogenic gluten epitopes, 2) degradation of immunodominant gliadin peptides that resist intestinal proteases by exogenous endopeptidases, 3) decrease of intestinal permeability by blockage of the epithelial ZOT receptor, 4) inhibition of intestinal TG2 activity by transglutaminase inhibitors, 5) inhibition of gluten peptide presentation by HLA-DQ2 antagonists, 6) Modulation or inhibition of proinflammatory cytokines, and 7) induction of oral tolerance to gluten. These and other experimental therapies will be discussed critically.

 

PMID: 19766641 [PubMed - as supplied by publisher]

 

 

 

{mosgoogle}

 

{mos_sb_discuss:11}

 


 

 

Related Articles:

 

  • No comments found

Leave your comments

Post comment as a guest

0 Character restriction
Your text should be more than 25 characters
Your comments are subjected to administrator's moderation.
terms and condition.

Adsense Responsive BottomBanner